We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Paratek Pharmaceuticals Inc | NASDAQ:PRTK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.23 | 2.18 | 2.23 | 0 | 01:00:00 |
From Apr 2023 to Apr 2024
By Colin Kellaher
Paratek Pharmaceuticals on Tuesday said it agreed to be acquired by a pair of healthcare investors in a deal valued at up to $462 million, including the assumption of debt.
Under the agreement, healthcare-investment firm Gurnet Point Capital and investment and holdings company Novo Holdings would pay an initial $2.15 a share in cash for the Boston biopharmaceutical company, a 9.7% premium to Monday's closing price of $1.96.
Paratek said its shareholders would also receive contingent value rights tied to commercial milestone that are potentially worth another 85 cents a share, bringing the total potential deal value to $3 a share, a 53% premium.
The transaction is slated to close in the third quarter.
Novo Holdings is owned by the Novo Nordisk Foundation, a Danish organization that controls healthcare giant Novo Nordisk.
Trading in shares of Paratek was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 06, 2023 09:44 ET (13:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Paratek Pharmaceuticals Chart |
1 Month Paratek Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
